SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. SR One take an active role in the portfolio companies and work with management teams and our fellow venture investors to create significant value. Celebrating its 30th anniversary in 2015, SR One has invested $1B in more than 170 companies, and its current portfolio includes 40 private and public companies.